Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 8.4 %

Shares of AKTX opened at $1.09 on Thursday. Akari Therapeutics has a 12-month low of $0.85 and a 12-month high of $4.40. The stock has a 50-day moving average price of $1.13 and a 200-day moving average price of $1.60.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.